comparemela.com
Home
Live Updates
New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA : comparemela.com
New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA
/PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the National Medical Products Administration (the NMPA) of China has officially accepted the...
Related Keywords
China ,
United States ,
Chinese ,
Xia Yu ,
Kong Beihua ,
Wu Xiaohua ,
Department Of Obstetrics ,
Chinese Medical Association Gynecological Oncology Branch ,
Akeso Inc ,
Qilu Hospital Of Shandong University ,
Prnewswire Akeso Inc ,
National Medical Products Administration ,
Drug Administration Of The United States ,
Fudan University Cancer Hospital ,
Global Strategy ,
Cervical Cancer ,
Healthy China ,
Qilu Hospital ,
Shandong University ,
Drug Administration ,
Drug Evaluation ,
சீனா ,
ஒன்றுபட்டது மாநிலங்களில் ,
சீன ,
கிஷிய யூ ,
துறை ஆஃப் மகப்பேறியல் ,
உலகளாவிய மூலோபாயம் ,
ஆரோக்கியமான சீனா ,
சாண்டோங் பல்கலைக்கழகம் ,
மருந்து மதிப்பீடு ,
Takeso ,
Nc ,
Pharmaceuticals ,
Health Care Amp Hospitals ,
Medical Pharmaceuticals ,
Biotechnology ,
International Medical Approval ,
comparemela.com © 2020. All Rights Reserved.